Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents.
暂无分享,去创建一个
C. Anderson | A. Rheingold | E. Wong | G. Weisman | J. Golen | Ashley L. Fiamengo | Jennifer E. Sprague | Yijie Peng | Katrina S. Woodin | Evan A Southwick | Jennifer Sprague
[1] L. Zakharov,et al. Kinetic Inertness and Electrochemical Behavior of Copper(II) Tetraazamacrocyclic Complexes: Possible Implications for in Vivo Stability , 2005 .
[2] S. Achilefu,et al. Preparation and Biological Evaluation of Copper-64–Labeled Tyr3-Octreotate Using a Cross-Bridged Macrocyclic Chelator , 2004, Clinical Cancer Research.
[3] R. Boyle,et al. Ultrastable complexes for in vivo use: a bifunctional chelator incorporating a cross-bridged macrocycle. , 2004, Chemical communications.
[4] Weijun Niu,et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. , 2004, Journal of medicinal chemistry.
[5] Joonyoung Kim,et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. , 2003, Bioconjugate chemistry.
[6] D. Busch,et al. Synthesis, structure, and stability in acid of copper(II) and zinc(II) complexes of cross-bridged tetraazamacrocycles , 2003 .
[7] S. Ametamey,et al. Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. , 2003, Nuclear medicine and biology.
[8] Joonyoung Kim,et al. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. , 2002, Bioconjugate chemistry.
[9] M. Wuest,et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. , 2002, Journal of medicinal chemistry.
[10] R Laforest,et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] Daniel C. Hill,et al. Synthesis and Characterization of Cross-Bridged Cyclams and Pendant-Armed Derivatives and Structural Studies of Their Copper(II) Complexes , 2000 .
[12] S S Gambhir,et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[13] M. Welch,et al. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. , 2000, Bioconjugate chemistry.
[14] David E Reichert,et al. Labeling and in vivo evaluation of novel copper(II) dioxotetraazamacrocyclic complexes. , 2000, Nuclear medicine and biology.
[15] P. Cutler,et al. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] D. Busch,et al. Crystallographic Characterization of Stepwise Changes in Ligand Conformations as Their Internal Topology Changes and Two Novel Cross-Bridged Tetraazamacrocyclic Copper(II) Complexes. , 1999, Inorganic chemistry.
[17] G. Denardo,et al. Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. , 1999, Nuclear medicine and biology.
[18] J. Lewis,et al. In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake. , 1999, Nuclear medicine and biology.
[19] M. Welch,et al. The in vivo behavior of copper-64-labeled azamacrocyclic complexes. , 1998, Nuclear medicine and biology.
[20] J. Erion,et al. Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-D-Phe1-octreotide. , 1998, Bioconjugate chemistry.
[21] E P Krenning,et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. , 1998, Cancer research.
[22] T. Visser,et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy , 1997, European Journal of Nuclear Medicine.
[23] M. Welch,et al. Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. , 1996, Bioconjugate chemistry.
[24] M. Welch,et al. Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Rogers,et al. Cross-bridged cyclam. Protonation and lithium cation (Li+) complexation in a diamond-lattice cleft , 1990 .
[26] S. Denardo,et al. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. , 1985, Analytical biochemistry.
[27] C. Anderson,et al. Optimization of labeling and metabolite analysis of copper-64-labeled azamacrocyclic chelators by radio-LC-MS. , 2005, Nuclear medicine and biology.
[28] D. Busch,et al. Ultra rigid cross-bridged tetraazamacrocycles as ligands—the challenge and the solution , 1998 .
[29] M J Welch,et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. , 1997, Nuclear medicine and biology.
[30] Daniel C. Hill,et al. Synthesis and transition-metal complexes of new cross-bridged tetraamine ligands , 1996 .
[31] G. Denardo,et al. Comparative serum stability of radiochelates for antibody radiopharmaceuticals. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] G. Denardo,et al. Serum stability of 67Cu chelates: comparison with 111In and 57Co. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.